OKYO Pharma Limited
Support and Resistance Levels
Past performance
News About OKYO
All events for OKYO
All deals for OKYO
Financial Ratios
Financial Statements
OKYO vs Sector & Peers
About OKYO Pharma Limited
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK. Website okyopharma.com
Headquarters London, GL, GB